Fig. 3.

Complex-induced enhancement in antibody quality is associated with protection. a The relationship between time-to-patency and in vitro growth inhibitory activity of purified IgG for the 16 animals in Groups 2 (blue) and 3 (red). Spearman’s rank correlation coefficient (r _s) and P value are shown for the relationship of time-to-patency and in vitro growth inhibitory activity of purified IgG from the same animals. The horizontal dotted line represents the 50% GIA and the vertical dotted line separates the animals that either had a significant delay in patency (>15 days) or were SP until the end of the study. b Anti-PfAMA1(FVO) antibody levels do not correlate with in vitro growth inhibitory activity (r _s = −0.082, P = 0.76). c The relationship between anti-PfAMA1(FVO) antibody levels and time-to-patency shows no correlation (r _s = −0.008, P = 0.94). GIAs were performed at 2.5 mg mL⁻¹ total IgG from each immunized animal